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Background: It is clear that the coordinated and reciprocal actions of kinases and phosphatases are fundamental in
the regulation of development and growth of the malaria parasite. Protein Phosphatase type 1 is a key enzyme
playing diverse and essential roles in cell survival. Its dephosphorylation activity/specificity is governed by the
interaction of its catalytic subunit (PP1c) with regulatory proteins. Among these, inhibitor-2 (I2) is one of the most
evolutionarily ancient PP1 regulators. In vivo studies in various organisms revealed a defect in chromosome
segregation and cell cycle progression when the function of I2 is blocked.
Results: In this report, we present evidence that Plasmodium falciparum, the causative agent of the most deadly form
of malaria, expresses a structural homolog of mammalian I2, named PfI2. Biochemical, in vitro and in vivo studies
revealed that PfI2 binds PP1 and inhibits its activity. We further showed that the motifs 12KTISW16 and 102HYNE105 are
critical for PfI2 inhibitory activity. Functional studies using the Xenopus oocyte model revealed that PfI2 is able to
overcome the G2/M cell cycle checkpoint by inducing germinal vesicle breakdown. Genetic manipulations in P.
falciparum suggest an essential role of PfI2 as no viable mutants with a disrupted PfI2 gene were detectable.
Additionally, peptides derived from PfI2 and competing with RVxF binding sites in PP1 exhibit anti-plasmodial activity
against blood stage parasites in vitro.
Conclusions: Taken together, our data suggest that the PfI2 protein could play a role in the regulation of the P.
falciparum cell cycle through its PfPP1 phosphatase regulatory activity. Structure-activity studies of this regulator led to
the identification of peptides with anti-plasmodial activity against blood stage parasites in vitro suggesting that PP1c-
regulator interactions could be a novel means to control malaria.
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During its life cycle, Plasmodium falciparum, the deadli-
est malaria parasite for humans, undergoes several suc-
cessive rounds of mitosis to amplify parasite populations
and consequently to increase the rate of its transmission.
Among the essential actors in the growth and division
of the parasite are kinases and phosphatases. Indeed, ini-
tial experiments using inhibitors of these enzymes, such
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reproduction in any medium, provided the orparasite growth in vitro [1-3]. Subsequently, the identifi-
cation of kinases and phosphatases and their central
functions in P. falciparum [4-9] demonstrated that phos-
phorylation and dephosphorylation represent a key post-
translational modification regulating the activities of a
variety of proteins. The former process is supported by a
recent high-throughput phosphoproteomic studies of
blood stage parasites that identified around 7000 phosphor-
ylation sites on ~ 28% of proteins [4,10-12]. Of note is that
the profile of the reported phosphoproteome reflects the
global status of proteins resulting from a balance between
endogenous kinase and phosphatase activities. In vivo stu-
dies, knocking down kinases in Plasmodium, and high-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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kinase inhibitors against blood stage parasites confirmed ki-
nases as important drug targets [13-16].
Among the phosphatases, PP1 has been identified in
P. falciparum (PfPP1c) and it accounts for the major
phosphatase activity in total parasite extracts [1,17,18].
The use of potent inhibitors of phosphatases showed
that P. falciparum predominantly expressed PP1-like
activity which appears to control parasite growth and
seems to be involved in the release of infectious merozo-
ites [19,20]. In the past decade, a vast body of research
has provided converging evidence that the key mechan-
ism of the mode of action of the PP1c subunit resides in
the presence of interacting regulators that direct the
proper functions of this phosphatase (i.e. localization,
specificity and the level of activity) [21-23]. At present,
there are about 200 PP1 interacting proteins among
which about 100 have been identified as regulatory sub-
units of PP1c [24-26]. The majority of regulators that in-
hibit the phosphatase activity interact with PP1c through
an amino acid sequence present in the regulator and
designated as the ‘RVxF’ motif. The consensus sequence
[R/K]X0-1[V/I](p)[F/W], where X can be any amino acid
and (p) any residue except proline, has been defined as a
canonical PP1-binding site [27]. With respect to the
endogenous regulators of PP1 and in comparison to
other organisms, very few have so far been identified in
P. falciparum, although we previously reported the iden-
tification of two regulators, PfLRR1 and Pf inhibitor-3
[28,29]. Characterization studies have shown that both
regulators interact with PfPP1 and are present in the nu-
cleus of blood stage parasites. Functional assays revealed
that PfLRR1 dramatically decreased PfPP1 activity, like
its homologues in other organisms [28]. Unexpectedly,
PfI3 strongly increased PfPP1 activity in vitro and was
unable to rescue yeast deleted for the expression of its
ortholog. These data suggest that these regulators con-
trol PP1 activity in the nucleus and underscore the need
for a better understanding of the function of PP1 regula-
tors in each species [29].
A database search with Inhibitor-1 (I1) and Inhibitor-2
(I2), known to be powerful regulators of PP1c, identified
one open reading frame in the P. falciparum genome
(PlasmoDB gene identifier: PF3D7_0320000) encoding a
potential protein with identity to known I2. Inhibitor-2
is a thermo- and acid-stable regulator initially purified
from rabbit skeletal muscle and is conserved among all
eukaryotes [30,31]. The potency of the inhibition by re-
combinant I2 of different species measured in parallel
seems to be species specific in terms of inhibitory effect
[32]. It is interesting to note that the peptide sequences
of I2 orthologs vary in length, from 164 amino acids in
plants up to 205 amino acids in humans. This may ac-
count for specificities mentioned above. The comparisonof I2 sequences of different species along with in vitro
functional studies revealed that two main regions par-
ticipate in the interaction with PP1c and the inhibition
of its activity: one binding region containing a KSQKW
motif suggested to fulfill the role of the canonical RVxF
motif and a second region containing a HYNE motif
[33,34]. In addition, a third region present in the N-
terminal moiety of human I2 and containing a KGILK
motif has also been shown to be involved in the inter-
action with PP1c [34-36]. The resolution of the rodent
PP1c-I2 crystal structure confirmed the implication of
these regions in the binding process [37].
In vivo, the overexpression of GLC8 (a yeast I2
homologue) or the knockdown of human I2 by RNA
interference showed its direct role in the cell cycle
[38,39]. For instance, human I2 knockdown produced
multinucleated cells during anaphase and blocked cyto-
kinesis [39]. Moreover, exploration of the role of I2 in
Drosophila development evidenced that an I2 loss-
of-function in mothers leads to a dramatic reduction in
the viability of progeny as measured by a decrease in
embryonic hatch rates and larval lethality. However, I2
gain-of-function by transgenic expression of I2 in mu-
tant mothers reversed this effect [40]. Altogether, these
observations indicate that I2 plays a critical role in
achieving successful mitosis and it is apparent that
interfering with I2 functions represents an attractive
approach for pharmacological intervention. Here, we re-
port the structure-function relationship of inhibitor-2 of
P. falciparum (PfI2) and explore its role and the means
to affect its function in the parasite.
Results
Cloning and bioinformatics analysis of Pf Inhibitor-2
Analysis of PlasmoDB [41] using the human Inhibitor-
2 sequence (CAA55475) identified a gene (gene identi-
fier PF3D7_0320000) encoding a potential P. falciparum
Inhibitor-2 homolog (PfI2). To establish the identity of
the PfI2 sequence, we determined the nucleotide sequence
by RT-PCR using cDNA from total RNA of blood stage par-
asites and primers specified in Additional file 1: Table S1.
The amplification showed a PCR product of the predicted
size, confirming its transcription and the microarray data
available in PlasmoDB. A walking approach on cDNA from
the untranslated 5′ and 3′ ends allowed the validation of
the start and stop codons respectively. The deduced amino
acid sequence of the open reading frame corresponds to a
protein containing 144 amino acids, indicating that PfI2 has
the shortest amino acid sequence among I2 homologs
(Additional file 2: Figure S1). Sequence alignment com-
bined with visual inspection of PfI2 showed an overall
identity of 28% and 34% identity between amino acids at
positions 5 to 105 of PfI2 when compared to human I2
(Figure 1A). The use of PSORTII software [42] revealed a
Figure 1 Bioinformatic analysis. A. Comparison between the deduced amino acid sequence of P. falciparum inhibitor 2 (PfI2) and Human
inhibitor 2. (PlasmoDB gene identifier: PF3D7_0320000) was aligned with the Human Inhibitor 2 (HuI2 (Genbank accession number: NM_006241)
homologous using the ClustalW algorithm and was manually corrected. The identical residues are shown by a star. Amino acids are numbered at
the right of the sequence. The first box contains the “KGILK” motif, the second the “RvXF” motif and the third, the “HYNE” motif. The amino acids
involved in the putative nuclear localization signal are shown in light gray. B. Known interaction sequences between Human I2 and PP1 were
compared to PfI2 sequences. C. Predicted PfI2 structure. The helices are represented by a cylinder, the coils are represented by a line. D. Phylogenic
tree of the Inhibitor 2 family. A maximum likehood tree was generated from the 21 inhibitor-2 sequences using MEGA5 under the JTT + G + I model
with 100 bootstrap repetitions. Outgroups are formed by inhibitor 3 orthologs (I3, outgroup 1) and sds22 like proteins (LRR1, outgroup 2).
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98KRKKHYNEYKMLQKLRK114) (Figure 1A). The PfI2
protein contains two peptides KTISW and KHYNE that
fit perfectly to the [R/K]X[V/I]X[F/W] or RVxF motif
and [K/R]HYNE motifs responsible for binding to PP1c
(Figure 1B). However, 2 main differences were observedbetween PfI2 and human I2 proteins. First, the KGILK
sequence, found in human I2 and shown to be required
for interaction with PP1c [34-36] is not present in the
PfI2 sequence and second, the KSQKW sequence of
human I2 contains a Q residue instead of V or I of the
RVxF consensus sequence (Figure 1A,B). The analysis of
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ware PsiPred [43,44] predicted that the RVxF motif is a
part of an unstructured region, while the HYNE motif is
within an α-helix occurring between positions 70 and
120 (Figure 1C). This structure is in agreement with
that identified in mammalian I2 [37]. This analysis is in
accordance with the structure prediction presented in
PlasmoDB [41].
A maximum likehood phylogenetic tree was generated
under the JTT + I + G model with the support of two
outgroups composed of two well described PP1 regula-
tors: Inhibitor 3 (I3, outgroup 1) and LRR1 (outgroup 2)
[28,29,45,46]. In this tree (Figure 1D) PfI2 segregates
with orthologues from other Plasmodium species as well
as the apicomplexan Theileria parva, but within the I2
family on a well-supported branch (bootstrap analysis)
separate from the I3 family. This analysis clearly identi-
fies PfI2 as a PP1c inhibitor 2 family member.Figure 2 Expression and localization of the PfI2 gene product by P. fa
blotted onto nitrocellulose (Red Ponceau staining, lane 1) and revealed wit
an anomalous electrophoretic migration of PfI2 (expected size 16.7 kDa). Th
MALDI-TOF mass spectrometry. B. Immunoprecipitation of native PfI2 with
followed by an immunoblot analysis with preimmune serum (lane 1) or wi
extracted from asynchronous cultures of P. falciparum using PfPP1 column. To
incubated overnight with His6-PfPP1 affinity Ni-NTA column as described in M
(lane 2) or with anti-His mAb antibodies (lane 3). The blots were revealed as d
transfected P. falciparum. Protein extracted from wild-type parasites (lane 1) o
and probed with anti-GFP mAb antibodies. E. Expression and localization of P
were transfected with pARL2-PfI2-GFP construct as described in Methods andExpression of PfI2 protein by P. falciparum and
localization studies
To investigate the expression of PfI2 by P. falciparum,
polyclonal antibodies against the recombinant PfI2
protein were raised. As presented in Figure 2A lane 1
(Red Ponceau staining), the recombinant protein whose
amino acid sequence was confirmed by MALDI-TOF
mass spectrometry, migrated at about 20 kDa, in agree-
ment with the anomalous electrophoretic behavior of
inhibitors of the PP1 family; the expected molecular
weight of endogenous PfI2 is 16.7 KDa. Although these
antibodies recognized the recombinant protein (Figure 2A,
lane 2), they were unable to react with any bands in total
extracts of asynchronous blood stage parasites. In order to
detect endogenous PfI2, we carried out immunoprecipita-
tion experiments with anti-PfI2 sera or pre-bleed sera with
total parasite extracts. Immunoblots with anti-PfI2 anti-
bodies showed the presence of a band at 20 kDa in thelciparum. A. Purified His6-PfI2 separated by 15% SDS-PAGE and
h mAb anti-His (lane 2) showed a single band at ~ 20 kDa, indicating
e identity of the purified recombinant PfI2 was further confirmed by
anti-PfI2 polyclonal antibodies from Plasmodium falciparum extracts,
th anti-PfI2 antisera (lane 2). C. Detection of PfI2 in total proteins
tal protein extracts (10 mg) pre-cleared on Ni-NTA sepharose beads were
ethods. The blots were probed with preimmune serum (lane 1), anti-PfI2
escribed in Methods. D. Immunoblot analysis of pARL2-PfI2-GFP
r from transfected parasites (lane 2) were subjected to western-blotting
fI2-GFP throughout the erythrocytic cell cycle of P. falciparum. Parasites
live transfectants were analysed by fluorescence microscopy.
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while the pre-bleed serum detected no specific band
(Figure 2B, lane1). To confirm this expression and to
examine whether native PfI2 could be among the part-
ners of PfPP1, we performed affinity purification from
total parasite extracts using recombinant His-tagged
PfPP1 retained on Ni-NTA agarose beads. As depicted
in Figure 2C, immunoblot analysis of eluates with
anti-PfI2 antibodies (lane 2) reacted with one band at
20 kDa, corresponding to the migration of the recom-
binant PfI2 protein. Lane 3 confirmed the presence of
His-tagged PfPP1 by the use of mAb anti-His antibody.
To accurately follow up the distribution of PfI2 during
the intraerythrocytic development cycle, we examined
3D7 parasites transfected with a pARL2 construct medi-
ating the episomal expression of full-length GFP-fused
PfI2. The use of this vector by Kuhn et al. showed that
the trafficking was attributable to the nature of the pro-
tein expressed rather than to the PfCRT promoter used
[47]. Using a mAb anti-GFP antibody, immunoblot ana-
lysis of a total extract of blood stage parasites expressing
PfI2-GFP revealed the presence of a specific band at
37 kDa, which is the expected molecular mass of PfI2-
GFP (Figure 2D, lane 2). This demonstrates the integrityFigure 3 Targeted gene disruption and HA-tagging of the PfI2 locus.
recombination. The pCAM-BSD construct, the blasticidin-resistance cassette
PCR analysis and the locus resulting from integration are indicated. B. Inser
Analysis of pCAM-BSD-PfI2 transfected 3D7 culture by PCR (Knock-out strat
lanes 5–8 to DNA extracted from transfected parasites. Lanes 1 and 5 repre
lanes 2 and 6, the detection of wild type locus (Pr19 and Pr22); lanes 3 and
and 8 show the detection of the integration at the 5′end of the insert (Pr2
DNA prepared from transfected parasite culture (Pr27 and Pr26) indicated t
pCAM-PfI2-2HA transfected 3D7 culture (Knock-in strategy)). Lanes 1–4: DN
transfected parasites. Lanes 1 and 5: detection of a portion of wild type loc
and Pr22); lanes 3 and 7: detection of episomal DNA (Pr25 and Pr28) and la
(Pr19 and Pr28). The amplification of a PCR product at ~ 1000 pb using ge
indicated the homologous recombination and integration of the 2-HA conof the fused protein in transfected parasites. Examination
of live parasites showed that the signal was confined within
the parasite where the distribution seemed to be nucleo-
cytoplasmic (Figure 2E), as the fluorescence partially
overlapped DNA staining. The distribution appeared to be
diffuse in the late parasite stages with most staining in the
nucleus. These results are in accordance with previous
localization studies carried out on mammalian [48,49] or
plant [50] cells showing a nucleo-cytoplasmic localization
with an accumulation in the nucleus when human cells
progressed into S phase [48]. The PfI2-GFP signal was com-
pletely absent from the digestive food vacuole (Figure 2E).
Genetic manipulation of PfI2
To study whether the lack of PfI2 expression could
affect the Plasmodium blood stage life cycle, attempts to
disrupt the PfI2 gene using the pCAM vector system
were carried out. We transfected blood ring stage para-
sites of the 3D7 strain with a pCAM-BSD-PfI2 construct
containing a 5′ fragment derived from the genomic PfI2
sequence and the BSD gene conferring resistance to
blasticidin (Figure 3A). The presence of this construct in
transfected parasites was checked by a plasmid rescue
approach as previously described [29] (data not shown).A. Disruption of PfI2 by knock-out strategy using single homologous
(BSD), the location of the primers (Additional file 1: Table S1) used for
tion of an HA epitope tag at the PfI2 C terminus (Knock-in strategy). C.
egy). Lanes 1–4 correspond to DNA extracted from wild type parasites,
sent the detection of a portion of wild type locus (Pr19 and Pr20);
7 show the detection of episomal DNA (Pr25 and Pr26) and lanes 4
7 and Pr26). The absence of PCR product amplification using genomic
he lack of homologous recombination (lane 8). D. PCR analysis of
A extracted from wild type parasites; lanes 5–8: DNA extracted from
us (Pr21 and Pr22); lanes 2 and 6: detection of wild type locus (Pr19
nes 4 and 8: detection of the integration at the 3′end of the insert
nomic DNA prepared from transfected parasite culture (Pr19 and Pr28)
struct in endogenous PfI2 (lane 8).
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analysis of genomic DNA obtained from resistant stable
parasites by PCR (from 2 months up to 9 months of
culture under blasticidin pressure), with specific primers
indicated in Additional file 1: Table S1, did not evidence
the interruption of the PfI2 gene (Figure 3C, lane 8).
The wild type gene was still amplified in genomic DNA
even after prolonged culture (> 9 months of culture) and
the plasmid remained episomal.
The absence of knock-out parasites could be attributed
either to the essentiality of PfI2 or to the lack of accessibil-
ity of PfI2 to genetic manipulations. To exclude the latter
hypothesis and to check the accessibility for recombin-
ation of the PfI2 locus, we introduced a targeted modifica-
tion in the locus without loss-of-function. To this end,
3D7 ring stage parasites were transfected with a plasmid
containing the 3′ end of the PfI2 coding region fused to
the hemagglutinin sequence (Figure 3B). Genotype ana-
lysis by PCR, using one specific primer of PfI2 derived
from the upstream region of the construct PfI2-HA and a
primer corresponding to the hemagglutinin sequence
showed the presence of a specific PCR product at the
expected size, indicating the correct integration of PfI2-
HA into the locus (Figure 3D, lane 8). Taken together,Figure 4 Effect of PfI2 on PfPP1 phosphatase activity. A. Scheme of Hi
in this study. Recombinant PfPP1 was pre-incubated for 30 min at 37°C with d
(D), PfI2W16A (E) and PfI2Y103A (F) proteins before the addition of pNPP. Res
four independent experiments performed in duplicate.these data suggest the essentiality of PfI2 for the survival
of blood stage parasites.
Effect of PfI2 on Phosphatase activity of PfPP1
Next, we assayed PfI2 for its potential capacity to regulate
PfPP1 activity. As previously described, PfPP1 produced
as a recombinant protein dephosphorylates the pNPP sub-
strate, is sensitive to known PP1 inhibitors and its activity
is Mn2+-dependent [28]. Using a concentration of recom-
binant PfPP1 within a range producing linear release of
phosphate, the effect of wild-type recombinant (PfI2WT),
deleted or mutant recombinant PfI2 proteins was evalu-
ated as described in Methods. Deleted or mutated PfI2
versions presented in Figure 4A were produced as recom-
binant proteins and used in the functional assay. Results
showed a strong decrease (up to 80% inhibition) in the
phosphatase activity when PfPP1 was pre-incubated with
PfI2WT (Figure 4B). As PfI2 contains the 2 main motifs,
12KTISW16 (RVxF consensus motif) and 102HYNE105,
known to be essential for the function of Inhibitor-2, we
explored the impact of these motifs on PfI2 function in
terms of PP1 inhibition. The deletion of either the Nt
(PfI2(19–144)) or Ct (PfI2(1–94)) portion containing the
RVxF and HYNE motifs of PfI2 respectively abolished itss-tagged recombinant wild-type, deleted and mutated PfI2 proteins used
ifferent concentrations of PfI2WT (B), PfI2(1–94) (C), PfI2(19–144)
ults presented as% of relative increase or decrease are means ± SEM of
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When the PfI2W16A mutant protein was tested, we
observed that this mutation led to an almost complete loss
of function of PfI2, whatever the concentration of
PfI2W16A used (Figure 4E). The PfPP1 activity detected
was identical to the control. In the case of the PfI2Y103A
mutant protein, a loss of function was observed at the
lowest concentration, however, at higher concentrations of
PfI2Y103A a decrease of up to ~50% of PfPP1 activity was
observed (Figure 4F), suggesting that this mutation only
partially affected the function of PfI2. These data suggest
that the RVxF motif is the major contributor for the func-
tion of PfI2.
Study of PfI2-PfPP1 interaction and mapping of binding
motifs
The loss of function of deleted/mutated PfI2 observed
above may be related to its failure to interact with PfPP1.
Hence, the binding capacity of wild-type, deleted andFigure 5 Study of PfI2-PfPP1 interaction and mapping of binding mo
constructs were inserted into mat α (Y187) yeast and pGADT7, pGADT7-PfI
pGADT7-PfI2Y103A constructs into mat a (AH109) yeast. These transformati
LW plates (B) and interactions were identified by growth on SD-LWH (C) o
diploids revealed with mAb anti-Gal4-AD (E) or mAb anti-Gal4-BD (F) show
(PfI2WT: lanes 4,5,6; PfI2(1–94): lanes 7,8,9; PfI2(19–144): lanes 10,11,12; PfI2W
tagged laminin : lanes 2,5,8,11,14,17 or Gal4-BD tagged PfPP1: lanes 3,6,9,12mutated PfI2 with PfPP1 was assessed using the yeast two-
hybrid system. The interaction between PfPP1-Gal4-BD
and PfI2-Gal4-AD can be evidenced by growing diploid
strains on SDmedia lacking Leucine,Tryptophan, Histidine
(SD-LWH) or SD-LWHA (A for Adenine). Mating assays
between different strains are summarized in Figure 5A, in-
cluding those with control constructs. All mated strains
were shown to be able to grow on SD-LW (Figure 5B), indi-
cating that they contained the PfI2 and PfPP1 constructs.
Western blot analysis showed the expression of tagged
PfPP1 (anti-BD-Gal4 antibody) (Figure 5F) and the expres-
sion of PfI2 (anti-AD-Gal4 antibody) (Figure 5E). The
diploid strains containing PfPP1 and PfI2WT or deleted/
mutated PfI2 (PfI2(19–144), PfI2W16A or PfI2Y103A)
showed similar growth of these strains on SD-LWH media
(Figure 5C), indicative of an interaction with PfPP1. How-
ever, the diploid strains containing PfPP1 and PfI2(1–94) or
control plasmids were unable to grow. When stringent cul-
ture conditions were applied using SD-LWHA medium,tifs in yeast two hybrid system. pGBKT7, pGBKT7-lam, pGBKT7-PfPP1
2, pGADT7-PfI2(1–94), pGADT7-PfI2(19–144), pGADT7-PfI2W16A and
ons were followed by mating (A). Yeast diploids were checked on SD-
r SD-LWHA (D). Western-blot analysis of extracts prepared from yeast
ing the expected expression of the Gal4-AD tagged PfI2 proteins
16A: lanes 13,14,15 and PfI2Y103A: lanes 16,17,18) and Gal4-BD
,15,18.
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or PfPP1-PfI2W16A were still able to grow while the strain
containing PfPP1-PfI2Y103A lost its capacity for growth
(Figure 5D), suggesting a role for Y103 in the stability of the
interaction. Taken together, these results suggest that the
loss of function of most deleted or single mutated PfI2 pro-
teins is not due to a loss of interaction with PfPP1.
Initiation of G2/M in Xenopus oocytes by PfI2
The partial conservation in PfI2 of two PP1 binding mo-
tifs likely suggests a capacity to interact with other PP1
(highly conserved between species >80% identity) and to
exert a potential function. Previous studies reported that
the inhibition of PP1 in Xenopus oocytes by anti-PP1
antibodies triggered G2/M transition measured by the
appearance of Germinal Vesicle Break Down or GVBD
[51]. Having established the inhibitory role of recombin-
ant PfI2 on the phosphatase activity of PfPP1 in vitro, we
followed up the induction of GVBD by microinjecting the
wild or mutated His-tagged PfI2 proteins. Also, we evalu-
ated the ability of Nt deleted PfI2 (PfI2(19–144)) to trigger
G2/M transition as it is still able to bind PP1 in the ab-
sence of the RVxF motif. Results presented in Figure 6A
indicated that PfI2WT was able to induce GVBD (~ 85%).
Under the same conditions, PfI2(19–144), PfI2W16A or
PfI2Y103A proteins were ineffective in inducing GVBD.
The presence of each protein in microinjected oocytesFigure 6 Initiation of G2/M transition in Xenopus oocytes by PfI2. App
are presented as percentages. Each experiment was performed using a set
GVBD induced with 100 ng of PfI2WT, PfI2(19–144), PfI2W16A or PfI2Y103A
from injected oocytes revealed with mAb anti-His showing the presence o
with Xenopus PP1. Immunoblot analysis using specific anti-XePP1 antibodie
immunoprecipitation with anti-His mAb (lanes 3,6,9) (or anti-rabbit used as
(lanes 3,6). D. Percentage of GVBD induced by the pre-injection of PfI2(19–
(100 ng). PfI2WT injection was used as a positive control.was checked by immunoblots using anti-His mAb
(Figure 6B). In parallel, it was essential to check whether
PfI2WT can bind to Xenopus PP1 (XePP1). As shown in
Figure 6C, the use of a specific PP1 antibody for immuno-
blot analysis of eluates co-immunoprecipitated with anti-
His mAb revealed the presence of XePP1 in the complex
(lane 3, lane 6). The complex PfI2WT-XePP1 was detected
in Xenopus extracts 15 mn post micro-injection (lane 3).
The loss of functions of PfI2(19–144), PfI2W16A and
PfI2Y103A, combined with the fact that they retain their
capacity to bind to PfPP1, prompted us to examine their
capacity to block the function of PfI2WT. For this, oo-
cytes were pre-injected with the deleted or mutated PfI2
proteins, incubated for 2 hr and followed by the injec-
tion of PfI2WT. Results showed that PfI2(19–144) as well
as PfI2W16Awere able to completely abrogate the function
of PfI2WT as no GVBD was observed (Figure 6D). How-
ever, PfI2Y103A did not inhibit the function of PfI2WT.
Inhibition of PfI2 function by synthetic peptides
From the above results, it appears that W16 and Y103 of
PfI2 are critical residues within the KTISW (RVxF) and
HYNE motifs for binding/inhibition of PP1 with a stron-
ger role for the former. In addition, mutated PfI2 blocked
the function of the full-length PfI2WT. Consequently, we
investigated whether synthetic peptides containing these
motifs (Figure 7A and Additional file 3: Table S2) couldearance of GVBD was monitored for 15 h after injection, and values
of 20 oocytes and was repeated at least three times. A. Percentage of
recombinant proteins. B. Immunoblot analysis of extracts prepared
f each recombinant protein after microinjection C. Interaction of PfI2
s of naïve (lanes 1,4,7) or PfI2WT injected oocytes extracts after co-
control (lanes 2,5,8)) revealed the presence of XePP1 in the complex
144), PfI2W16A or PfI2Y103A (100 ng) 2 hours before PfI2WT injection
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ELISA based experiments we found that PfPP1 was able
to bind specifically to peptides containing either the
KTISW (RVxF) or HYNE motifs (Figure 7B). A higher
capacity of PfPP1 to bind the KTISW-containing peptide
(P1) compared to the HYNE-containing peptide (P4) was
observed. Interestingly, in PfPP1 activity assays, and unlike
PfI2WT, the synthetic peptides did not exhibit any cap-
acity to inhibit PfPP1 activity (Figure 7C). The absence of
any effect of peptides alone on PP1 activity was further
confirmed in vivo as their microinjection into Xenopus
oocytes did not induce GVBD (Figure 7D). Hence, we in-
vestigated whether synthetic peptides are able to block
PfI2WT function as measured by GVBD induction. Oo-
cytes were pre-injected with peptides before the injection
of PfI2WT. Results presented in Figure 7E revealed that
the microinjection of either KTISW-containing peptide
(P1) or the HYNE-containing peptide (P4) almost com-
pletely abolished GVBD induction. Pre-injections of con-
trol peptides (P6 and P10) did not lead to any inhibition
of PfI2WT-dependent GVBD. Immunoblot analysis of co-
immunoprecipitates with anti-His mAb demonstrated that
the pre-injections of P1 or P4 peptides prevented theFigure 7 Role of synthetic peptides derived from PfI2. A. Schematic re
respectively, from the RVxF (11KKTISW16) and HYNE (102HYNE105) domains. P
negative controls. B. Interaction studies of P1, P4, P6, P10 with His6-PfPP1 i
quantities of biotinylated His6-PfPP1 were added to wells coated with pep
positive control. Results are representative of 4 independent experiments. C
Recombinant His6-PfPP1 at 27.03 nM (2.5 μg) was pre-incubated for 30 min
control) before the addition of pNPP. Results presented as % of relative inc
performed in duplicate. D. Initiation of G2/M in Xenopus oocytes by peptid
values are presented as percentages. Each experiment was performed usin
injection was used as positive control. E. Percentage of GVBD induced by t
injection (100 ng). PfI2WT injection was used as a positive control. F. Abolit
Extracts from oocytes pre-injected or not with peptides followed by PfI2WT
analysis revealed with specific anti-XePP1 antibodies revealed the presence
and 5) and in non-pre-injected extracts (lane 1) but not in the P1 and P4 pbinding of PfI2WT to XePP1 while the control peptides
did not (Figure 7F).
Effect of peptides competing with PfI2 on the growth of
blood-stage P. falciparum parasites
The ability of synthetic peptides to block the effect of
PfI2WT using the Xenopus model, combined with the
observation suggesting that PfI2 is essential in P. falcip-
arum blood-stage parasites, led us to evaluate the
capacity of these peptides to inhibit the growth of P. fal-
ciparum in vitro. The synthetic peptides with repeated
motifs of either the RVxF motif (KTISW) (P8) or the
HYNE motif (P9) (Additional file 3: Table S2) did not
show any effect on parasite growth (not shown) which
could be due to very low or absence of peptide penetra-
tion. To improve and enhance peptide uptake, the pene-
trating peptide VKKKKIKREIKI (P6), previously shown
to act as a non-toxic shuttle to deliver peptides to
infected red blood cells [52] was coupled to the NH2
terminus of each repeated motif. As shown in Figure 8A,
the peptide P1 containing the KTISW motif inhibited
parasite growth in a dose dependent manner with an in-
hibition of ~80% at a concentration of 80 μM. Negativepresentation of PfI2 sequence and P1 and P4 peptides derived,
6 (penetrating peptide) and P10 (P1 mutated version) were used as
n vitro using ELISA based quantification of binding capacity. Increasing
tides (5 μg/well) or recombinant PfI2WT protein (5 μg/well) used as
. Effect of P1, P4, P6 and P10 on PfPP1 phosphatase activity.
at 37°C with different concentrations of peptides or PfI2WT (positive
rease or decrease are means ± SEM of four independent experiments
es. Appearance of GVBD was monitored for 15 h after injection, and
g a set of 20 oocytes and was repeated at least three times. PfI2WT
he pre-injection of P1, P4, P6 or P10 (100 ng) 1 hour before PfI2WT
ion of PfI2WT/XePP1 interaction after P1 and P4 peptides pre-injection.
injection were immunoprecipitated with anti-His mAb. Immunoblot
of XePP1 in the complex in P6 and P10 pre-injected extracts (lanes 4
re-injected extracts (lanes 2 and 3).
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trating peptide alone (P6) or to the mutated peptide
(P10) did not show specific inhibition. Regarding the
peptide containing HYNE (P4), no growth inhibition of
blood stage parasites was detectable (Figure 8B) (<10%
at 80 μM) although it was able to block the function of
PfI2WT in the oocyte model (Figure 7E).
To confirm the role of the RVxF competing peptide on P.
falciparum growth, a second motif (KVVRW) derived from
Pf Inhibitor-3, which we previously reported as the RVxF
motif of this inhibitor [29], was evaluated under the same
conditions. Results presented in Figure 8D indicate that the
peptide containing the KVVRW sequence (P5) did potently
reduce parasitemia (up to 90% of inhibition at a concentra-
tion of 80 μM), while the mutated corresponding peptide
(P11) exhibited a drastically reduced capacity to inhibit
parasite growth. As we observed a sigmoidal concentration
effect relationship, IC50 values for the active peptides were
calculated. Based on 7 independent experiments carriedFigure 8 Effect of synthetic peptides derived from PfI2 and PfI3 on b
3D7 P. falciparum strain parasites by PfI2 derived peptides. Parasites were in
in a 96-well microtiter plate. Parasitemia was quantified as described in Me
P6 (penetrating peptide alone) and P10 (mutated version of P1) were used
(Pf Inhibitor 3): P5 peptide corresponds to 41KVVRW45 (RVxF motif) and P11
growth of P. falciparum 3D7 by synthetic peptides derived from PfI3. Result
seven independent experiments performed in duplicate. E. IC50 values of P
stimulated primary mouse spleen cells. F. Selective penetration of FITC-labe
represents the DAPI staining, the middle panel represents the fluorescenceout on the 3D7 strain with 3 different batches of synthetic
peptides, IC50s were 23.76 μM for KTISW (P1) and
9.72 μM for KVVRW (P5) containing peptides respectively
(Figure 8E). When the effect of P1 and P5 peptides was
tested on the HB3 strain (2 different batches), the IC50s
were 14.99 μM and 8.79 μM respectively. Finally, the tox-
icity of these peptides was evaluated by their capacity to
block the proliferation of stimulated mouse spleen cells
in vitro. The calculated IC50 was 45.3 μM for the KTISW-
containing peptide and 59.32 μM for the KVVRW-
containing peptide (n = 3 independent experiments),
showing a selectivity index of 2 to 6 fold for P.falciparum
according to the peptide tested.
To further explore the uptake of active P1 and P5 pep-
tides by blood parasite stages, FITC-labeled peptides were
used. As shown in Figure 8F, FITC-P1 was only accumu-
lated within free merozoites, while FITC-P5 penetrated
infected red blood cells and concentrated within intra-
cellular parasites (Figure 8G upper panel) as well as freelood P. falciparum parasite growth. A and B. Inhibition of growth of
cubated with different concentrations of synthetic peptides for 72 hr
thods. P1 and P4 correspond to KTISW and HYNE motifs respectively.
as control peptides. C. Schematic representation of PfI3 sequence
is the mutated version of P5 used as control peptide. D. Inhibition of
s presented as% of parasite growth inhibition are means ± SEM of
1 and P5 against 3D7 and HB3 P. falciparum strains and against
led P1 (F) and P5 (G) peptides in P. falciparum 3D7. The left panel
signal and the right panel represents the bright field image.
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cells did not accumulate any FITC-peptide (Figure 8F,
Figure 8G).
Discussion
The Pf Inhibitor2 gene (PfI2) encodes a protein of 144
amino acids related to the I2 proteins of different organ-
isms, which are known to inhibit PP1c activity in vitro.
Of the three central regions identified in the I2 protein as
binding motifs to PP1, the KGILK, RVxF, and HYNE mo-
tifs, PfI2 contained only a consensus RVxF (12KTISW16)
and the 102HYNE105 sequences. The lack of KGILK in PfI2
was supported by bioinformatics analysis indicating the
absence of this sequence in all potential open reading
frames upstream of the PfI2 gene and was further con-
firmed by a 5′cDNA walking approach. The KGILK motif
present in vertebrate I2 was found to be involved in the
interaction with PP1 through the region of amino acids
50–59 in PP1c [37]. In addition, deletion of the N-
terminal side of I2 containing this site and mutation of the
first Lys or the Ile dramatically reduced the inhibition cap-
acity of I2 (>500 fold decrease) [33-35]. These observa-
tions emphasize the importance of this site in the binding
and activity of vertebrate I2, which represents a major dif-
ference compared with PfI2, which lacks this motif.
Concerning the RVxF site, vertebrate I2 does not contain
the canonical motif falling within the consensus sequence
[R/K]X0-1[V/I]X0-1[F/W]. However, studies on the crys-
tal structure of PP1c-I2 revealed that the sequence
KSQKW, where the consensus Val/Ile residue is replaced
by a Gln is docked in the PP1 groove, which usually binds
the RVxF motif [37]. Structure-activity studies on the im-
plication of KSQKW site showed that the mutation of Trp
in mammalian I2 drastically reduced the inhibitory activity
of I2 [33]. It is worth noting that almost all I2 proteins
contain Gln at the position of Val/Ile. However, in P.
falciparum, the I2 protein does contain an Ile in the RVxF
motif, a second important dissimilarity between PfI2 and
other I2 proteins. The comparison of PfI2 with putative I2
of Toxoplasma gondii or Neospora canium (TGGT1_1147
60, NCLIV_032710), revealed the presence of the con-
sensus RVxF sequence where V/I is replaced by Leu,
maintaining the hydrophobicity of the residue and
suggesting its conservation within other Apicomplexa par-
asites. Studies on the third site of interaction, HYNE, have
shown that the His and Tyr residues are important in the
interaction with PP1c and it has been proposed that this
motif functions as a ‘degenerate’ RVxF motif [33,53]. More
recent studies clearly showed that the region containing
the HYNE motif interacts directly with the active site of
PP1c (involving 272Tyr and 96Arg residues of PP1c) with a
major contribution of His and Tyr residues [33,37]. This
excludes completely the possibility of a competition of
binding to PP1c between the RVxF and HYNE motifs andsuggests that the His and Tyr residues of I2 promote the
displacement of the catalytic metal ion. In the PfI2 pro-
tein, these two residues are conserved.
Among the three binding sites of I2, the best-identified
and most widely found in PP1 partners is the [R/K]X0-1
[V/I]X0-1[F/W] consensus motif, which corresponds to
KTISW in PfI2. The presence of RVxF in about 25-30%
of eukaryotic proteins is not a sufficient indicator in it-
self to classify a protein as a PP1c regulator [54]. These
observations, together with the fact that PfI2 is the
shortest I2 protein identified so far (144 amino acids for
PfI2 versus 164–205 for other I2), the absence of one
binding site (KGILK) and the fundamental difference in
the RVxF motif (KTISW) raised the question of the cap-
acity of PfI2 to bind and to regulate PfPP1. Using wild-
type recombinant proteins, we showed that labeled
PfPP1 was able to bind to PfI2 and vice versa. This was
further validated by the use of a yeast two-hybrid system
that confirmed the interaction of wild-type PfI2 with
PfPP1c and suggested that it was strong since the mated
PfI2 and PfPP1 yeast strains were able to grow under
stringent conditions (SD-LWHA medium). In order to
explore the contribution of PfI2 RVxF and HYNE motifs
for the interaction with PfPP1, two types of construc-
tions were used, one deleted for the Nt moiety of PfI2
and the other with a single mutation in the RVxF motif.
Binding was unaffected on SD-LWH medium, whatever
the construction tested and only one strain, carrying the
PfI2 Y103A, mutant was unable to grow under the most
stringent conditions (SD-LWHA medium). These obser-
vations show that there is no one, major site of inter-
action in PfI2 unlike Pf Inhibitor-3 (PfI3), for which we
showed that the mutation of 16 W (localized within the
RVxF domain of PfI3) completely abolished its binding/
function [29]. PfI3 exhibits a totally disorganized struc-
ture and seems to bind first to PfPP1 via the RVxF
groove and folds afterwards to accomplish its function
[29]. Regarding I2, previous studies suggested a major
role for the RVxF motif along with secondary binding
sites which should be intrinsically structured for efficient
binding to PP1c [33-35]. PfI2 secondary structure ana-
lysis predicted that the RVxF motif is a part of an un-
structured region, while the HYNE is within an α-helix.
The role of this structure in PfI2-PfPP1c interaction was
substantiated by the lack of binding of PfI2 deleted for
the region containing the α-helix (PfI2 (1–94)). In the
case of mutated PfI2, the yeast two-hybrid method sup-
ported a role for 103Tyr (localized within the HYNE do-
main of PfI2) in the stabilization of PfI2-PfPP1 binding
under stringent culture conditions.
It has been shown that most I2 proteins are able to
drastically decrease PP1c activity towards different non-
specific substrates such as Phosphorylase A and pNPP
[34,35,38,50]. As expected, the addition of PfI2 in the
Fréville et al. BMC Biology 2013, 11:80 Page 12 of 19
http://www.biomedcentral.com/1741-7007/11/80nanomolar range significantly decreased PfPP1 activity
up to 80%. To investigate the impact of KTISW (RVxF)
and HYNE motifs on PfI2 regulatory activity we used
deleted or mutated recombinant proteins. The contribu-
tion of the RVxF motif (KTISW) is key to the function of
PfI2 as both Nt deleted PfI2 (PfI2(19–144)) and mutated
PfI2 (PfI2W16A) were unable to inhibit PfPP1 activity,
whereas the involvement of the HYNE domain seems to
be less important. Thus, although the PfI2W16A mutant
is still able to bind to PfPP1, 12KTISW16 is a vital and a
primary site for the inhibitory activity of PfI2. To further
evaluate the inhibitory activity of PfI2 and the role of the
two motifs, we took advantage of the Xenopus model
where oocytes are physiologically arrested in G2/M pro-
phase I [55,56]. The injection of Xenopus I2 (spanning 188
residues and containing the KGILK, KSQKW and HYNE
motifs) or anti PP1 antibodies into oocytes induced germi-
nal vesicle breakdown or GVBD [51,57]. Plasmodium I2 is
able to substitute for the Xenopus orthologue in this
system since the microinjection of PfI2WT into oocytes
promoted the progression to M phase, inducing GVBD
and co-immunoprecipitation experiments confirmed the
interaction of PfI2 with Xenopus PP1c. This confirmed
that PfI2 can function in cells without the need for the
KGILK site and are in accordance with previous studies
that showed the involvement of Xenopus I2 in the G2/M
transition in acellular extracts [57] or the implication of
Glc8 (yeast inhibitor 2) in the cell cycle [38-40]. Deletion,
mutation or RNA interference studies carried out on
inhibitor 2 have demonstrated its implication in the cell
cycle, chromosome segregation and embryogenic deve-
lopment [38,39,57]. In the case of PfI2, when deleted
PfI2 (PfI2(19–144)) lacking 12KTISW16 or mutated
PfI2 (PfI2W16A or PfI2Y103A) were microinjected, no
GVBD was observed, demonstrating the importance of
both PfPP1 binding sites in the functional capacity of PfI2.
Since the PfI2 mutated proteins are able to bind PP1 but
unable to inhibit its function we sought to determine
whether the pre-injection of deleted or mutated PfI2 pro-
teins may block the role of wild PfI2. The pre-injection of
either PfI2(19–144) or PfI2W16A were able to block the
induction of GVBD while PfI2Y103A did not. One explan-
ation for these observations is that the HYNE-dependent
binding is critical as the injection of PfI2WT is able to dis-
place this mutated protein and to induce GVBD. When
the HYNE site is not mutated the binding of PfI2 is suffi-
ciently stable to prevent its displacement.
Closer examination of the PfI2 peptide sequence revealed
the presence of a consensus PXTP motif (37PNTP40), also
present in other I2, in which the phosphorylation of the T
within this site abrogated the function of I2 [32,57]. In PfI2,
the replacement of T by D (mimicking phosphorylation)
did not impact either the binding or the function of PfI2
(not shown), tending to exclude the phospho-regulation ofI2 at this site. These data are in agreement with the recent
P. falciparum phosphoproteome characterization showing
the phosphorylation of PfI2 at positions T13, S48, S50, S115,
T117 and S142 [4], but not at T39 within the PXTPmotif. The
assessment of the impact of PfI2 phosphorylation will await
further investigations on these phosphorylated residues as
well as the “T”within the PXTPmotif. At this stage, it is im-
portant to mention that, beside the capacity to interact with
PP1c, human I2 has been shown to participate in a direct
kinase-dependent signaling network. It was found that I2
was able to bind and to activate Nek2 and Aurora-A kinases
[58,59]. For these functions, I2 seems to operate through its
C-terminal domain as the protein deleted in this domain
(I2(1–118)) failed to interact with these kinases, excluding a
role for the KGILK and RVxF motifs. Although the PfI2
sequence is 61 amino acids shorter than its human
homologue, the capacity of PfI2 to bind P. falciparum
kinases of the NIMA and Aurora families (for which active
recombinant enzymes are available [60-64]) should be
evaluated.
In P. falciparum, microarray analysis detected PfI2
mRNA in all blood parasite stages and gametocytes
(data available in PlasmoDB, [41]). In this work, co-
immunoprecipitation experiments with anti-PfI2 anti-
bodies followed by Western blotting and the use of a
PfPP1 affinity column clearly revealed the expression of
PfI2 protein by P. falciparum and of its capacity to bind
PfPP1. Transfection of live parasites with the tagged
PfI2-GFP protein showed that its distribution is
nucleocytoplasmic, like PfPP1 [28], with a strong accu-
mulation in the nucleus, is in agreement with the
localization of other I2 proteins [49]. Indeed mamma-
lian I2 fused to GFP was localized in both the cytoplasm
and the nucleus, with an active import to the latter
compartment, supported by the presence of two puta-
tive nuclear localization signals [49,65,66]. In the case of
PfI2, bioinformatics analysis also revealed a putative
nuclear localization signal, supporting its nuclear
localization. We previously reported that PfLRR1 and Pf
inhibitor-3, the first identified regulatory subunits of
PfPP1c, localized to the nucleus, evoking a specific role
in this compartment [28,29]. The present study suggests
an additional role for the PfI2 regulatory subunit of
PP1c, present in the nucleus but also in the cytoplasm.
Our reverse genetic studies strongly suggest a critical
role for PfI2 in the erythrocytic asexual cycle in vitro as
no parasites with a disrupted PfI2 gene were detectable.
Definition of the PfI2 role(s) during the life cycle neces-
sitates further work, requiring the development of a
powerful inducible expression system for P. falciparum.
The ability of PfI2 to bind and to inhibit PP1c both
in vitro and in cellular conditions (Xenopus oocytes)
through the two main motifs: the RVxF motif (KTISW)
and the HYNE motif, together with the fact that a tight
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functions, led us to explore whether derived ‘competing’
peptides from PfI2 could bind to PP1c and inhibit down-
stream signaling pathways. Only peptides containing the
KTISW or HYNE motifs were able to bind to PfPP1c.
However, the incubation of these peptides with PfPP1 or
their injection into oocytes failed either to inhibit
phosphatase activity or to promote GVBD respectively.
However, the pre-injection of the KTISW and HYNE
peptides did block the PfI2-dependent GVBD. Moreover,
there was no interaction between Xenopus PP1 and PfI2
in extracts of oocytes pre-injected with the KTISW or
HYNE peptides. This encouraged us to investigate the
ability of these peptides to inhibit the growth of P.
falciparum. To do this, the capacity of the peptides to
cross membranes was first improved by including a
short basic peptide, which has been shown to be highly
efficient in increasing the permeability of peptides and
to promote accumulation within infected red blood cells
[52]. Peptides encompassing the RVxF degenerate motif
R/KX0-1 V/I X0-1 F/W (KTISW or KVVRW) inhibited
the growth of 3D7 P. falciparum strain at low micro-
molar concentrations. The substitution of amino acids
essential for binding with PfPP1 validated that the
growth inhibition was RVxF-dependent. The difference
in the observed IC50 values of KTISW and KVVRW
containing peptides could be related to a higher affinity
of the latter for PfPP1 and the fact that it proved able to
accumulate not only in merozoites but also in parasites
within infected red blood cells. Unexpectedly, the second
PP1 binding peptide containing the HYNE motif, al-
though it was found functional in oocyte model, was not
active as an antiplasmodial suggesting that native PfI2
expressed by P. falciparum could displace the HYNE
peptide. One possible explanation for the anti-parasitic
activity of RVxF containing peptides is that an increase in
PP1 activity due to its reduced interaction with regulators
could result in uncontrolled protein dephosphorylation,
leading in turn to an inhibition of parasite differentiation/
growth. This implies that each competing active peptide
can block its respective protein but that cross-inhibition
of other partners using the same docking site cannot be
excluded. These peptides might prove very useful as fun-
damental research tools to dissect pathways and processes
controlled by PP1 in Plasmodium falciparum.
Conclusion
In this study we report the molecular analysis and func-
tional role of the inhibitor-2 regulator, a gene product that
binds to and controls the activity of PfPP1. Structure-
activity studies of this regulator led to the identification of
binding/functional motifs of PfI2. In addition, peptides
corresponding to the RVxF motif exhibit anti-plasmodial
activity against blood stage parasites in vitro. Although,additional investigations are required to better define the
interaction of competing peptides in the parasite, the
proof-of-concept finding of derived peptides from regula-
tors of PfPP1 that inhibit the binding of PfI2 to PfPP1 and,
in consequence, parasite growth is an important advance.
It opens new avenues for the design of novel anti-parasitic
therapeutics by screening large combinatorial libraries of
small compounds blocking the function of regulators of
PfPP1. Interestingly, a recent study showed that the select-
ive inhibition of GADD34, a human regulator of PP1, by
guanabenz (an a2-adrenergic receptor agonist) was able to
restore proteostasis and to protect stressed cells [67]. This
further confirms that interfering with the interaction of
PP1-regulators and/or dissociation of the complex can
help to better understand the role of PfPP1 and to create
new means to develop antimalarials.
Methods
Genome databases searches and sequences analysis
Putative Inhibitor 2 sequences were searched using BLASTp
on sequences available in GenBank [68], PlasmoDB
[41], ToxoDB [69], SchistoDB [70], Xenbase [71] and
OrthoMCLDB [72] databases. The human I2/Plasmo-
dium falciparum I2 sequences alignment was performed
using the ClustalW program and was manually corrected.
Phylogenetic analyses and secondary structure prediction
Protein sequences (listed in supplemental Additional file 4:
Table S3) were aligned using the ClustalW algorithm
implemented in the BioEdit v7.1 software, and manually
corrected. Maximum likehood trees were built using
MEGA5 [73] under the JTT + I + G model, with 100 boot-
strap repetitions. of the following species: Plasmodium
falciparum , Plasmodium berghei , Plasmodium chabaudi,
Plasmodium knowlesi, Plasmodium vivax, Plasmodium
yoeli yoeli,Toxoplasma gondii, Arabidopsis thaliana, Homo
sapiens, Mus musculus, Trypanosoma brucei, Tetrahymena
thermophila, Xenopus laevis (or tropicalis), Danio rerio,
Saccharomyces cerevisiae, Theileria parva, Drosophila
melanogaster, Leishmania major, Oryza sativa, cae-
norhabditis elegans and Schistosoma mansoni.
PfI2 secondary prediction was carried out using the
PsiPred software [43] and the potential nuclear signal
localization was performed using the PSORTII soft-
ware [42].
Plasmids
Plasmids pCR2.1-TOPO, pQE30, pGEX4T3, pETDuet-1,
pGADT7 and pGBKT7 were purchased from Invitrogen,
Qiagen, Life Sciences, Novagen and Clontech respect-
ively. Plasmid pCAM-HA, and pCAM were kind gifts of
Dr C. Doerig (Monash University, Australia). Monoclo-
nal anti-HA and anti-Myc antibodies were purchased
from Roche and Invitrogen respectively.
Fréville et al. BMC Biology 2013, 11:80 Page 14 of 19
http://www.biomedcentral.com/1741-7007/11/80Preparation of parasites
P. falciparum 3D7 and HB3 clones were grown according
to Trager and Jensen [74], in RPMI-1640 medium sup-
plemented with 0.5% AlbuMAX™ II (Invitrogen), 0.2 mM
Hypoxanthin (CCPro) and 20 μg/ml Gentamycin
(Invitrogen), in the presence of O+ erythrocytes. Parasites
were synchronized by a double sorbitol treatment as
previously described [75]. In order to isolate total RNA or
proteins, parasitized erythrocytes were prepared by
saponin lysis [76] and either resuspended in Trizol
(Invitrogen) or in phosphate buffered saline containing
EDTA-free protease inhibitor cocktail (Roche). For some
experiments, infected red blood cells were purified using
Percoll-sorbitol density gradients with slight modifications
[77]. Soluble protein extracts were prepared from
saponin-isolated parasites by suspending the pellet in lysis
buffer (20 mM Tris–HCl, Nacl 150 mM pH 7.4, 0.5%
Triton X-100, and protease inhibitors cocktail (Roche))
followed by 7 consecutive freezing/thawing cycles with
intermediate sonication steps and subsequent centrifuga-
tion at 13 000 rpm for 30 min at 4°C. Protein concentra-
tions in the supernatants were determined using the BCA
protein assay (Pierce).
Recombinant proteins expression and purification
Initial experiments with the wild-type PfI2 cDNA did not
allow the production of recombinant protein whatever the
bacterial plasmid and the condition of expression used.
In order to overcome this problem, a PfI2 gene with opti-
mized codons has been synthesized (eurofins, MWG
operon). The sequence is presented in Additional file 5:
Figure S2. This synthetic gene has been cloned in different
bacterial and yeast plasmids for interaction and functional
studies and used as template to obtain deleted and mu-
tated PfI2 proteins. Briefly, the full-length coding region of
PfI2WT, PfI2(1–94) and PfI2(19–144) were obtained by
PCR with the primers Pr1-Pr2, Pr3-Pr4 and Pr5-Pr6 re-
spectively (Additional file 1: Table S1) and subcloned in
pQE30. For the expression of PfPP1 (primers Pr11 and
Pr12), the pETDuet-1 expression system was used. The re-
striction sites are mentioned in Additional file 1: Table S1.
Before cloning in expression vectors, all PCR products
were subcloned in a pCR2.1-TOPO vector (Invitrogen)
and verified by sequencing for the absence of any modifi-
cation introduced by Taq polymerase.
To obtain the PfI2 mutant constructs, we performed
PCR-based site-directed mutagenesis using the construc-
tions pQE30-PfI2 or pGADT7-PfI2 as templates, the
primers Pr7-Pr8 (PfI2W16A) or Pr9-Pr10 (PfI2Y103A) and
using Isis Proofreading DNA polymerase (Qbiogene). The
PCR conditions consisted of 1 min at 95°C followed by 16
cycles at 95°C (30 s), 55°C (1 min) and 72°C (8 min). The
parental DNA plasmid was then digested with DpnI and an
aliquot was used to transform XL10-Gold Ultracompetentcells (Stratagene). Mutated plasmids were checked by se-
quencing for the replacement of tryptophan 16 and tyrosine
103 by an alanine and then used for the expression of mu-
tant PfI2 recombinant proteins or yeast two-hybrid assays.
Protein expression was carried out in the E. coli M15
strain for the pQE30 construct and the BL21 strain for
pETDuet-1 constructs. The expression of His6-PfI2 pro-
teins was carried out in the presence of 0.5 mM IPTG at
37°C for 2 hr. For the expression of His6-PfPP1, the
culture was induced overnight at 16°C in the presence of
0.5 mM IPTG and 1 mM MnCl2. Cells were harvested
in sonication buffer (20 mM Tris, 1% Triton X-100, lyso-
zyme 1 mg/ml, and protease inhibitor cocktail (Roche)).
His-tagged recombinant proteins were purified according
to manufacturer’s instructions by Ni2+ chelation chroma-
tography (GE Healthcare). With respect to the His6-PfI2
proteins, the extract was prepared using a 20 mM Tris
HCl (pH 7.4), 150 mM Nacl, 20 mM Imidazole and 6 M
guanidine buffer and loaded on a 1 ml nickel-NTA resin
column (HiTrap, GE Healthcare). Washing steps were
performed with a buffer containing 20 mM Tris HCl
(pH 7.4), 150 mM NaCl and 20 mM imidazole. The
imidazole-eluted proteins were dialyzed against 20 mM
Tris pH 7.4, 150 mM NaCl. Under these conditions, the
purity checked by SDS-PAGE followed by Coomassie-blue
staining was >95%. His6-PfI2 protein was further sub-
jected to peptide mass fingerprint by MALDI-TOF mass
spectrometry to confirm its identity.
For antisera production, the purified His6-PfI2WT was
mixed in Al(OH)3 (Alu-Gel-S, Serva) (100 μg per injec-
tion) and injected into rats (intra peritoneal route). Ani-
mals were boosted twice at intervals of 3 weeks with the
same quantity of His6-PfI2. The sera were obtained 2
weeks after the last boost and tested for their titres and
specificity by ELISA and Western-Blotting against recom-
binant proteins. Preimmune sera were used as negative
control.
Detection of PfI2 in P. falciparum erythrocytic stages
For Western blots, 60 μg/lane of P. falciparum soluble
proteins from synchronous and asynchronous cultures
were separated on a 4-12% SDS-PAGE and subsequently
blotted onto nitrocellulose. For the detection of PfI2, the
blots were probed with primary rat anti-PfI2 at 1:50. For
co- immunoprecipitation experiments, soluble parasite
extracts were incubated with anti-PfI2 polyclonal anti-
bodies in the presence of sepharose-protein G. After sev-
eral washings, the eluates were separated by SDS-PAGE
(4-12%gel) and transferred to nitrocellulose. Immuno-
blot analysis was performed with anti-PfI2 antibodies.
The detection of endogenous PfI2 in total proteins
extracted from asynchronous cultures of P. falciparum
were also carried out by using PfPP1 chromatography
column. Briefly, 10 mg of total protein extracts pre-
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night with His6-PfPP1 affinity Ni-NTA column. After
washings, proteins eluted with SDS-PAGE loading buffer
were migrated and blotted to nitrocellulose. The blots
were probed with preimmune serum anti-PfI2 or with
anti-His mAb antibodies. All secondary antibodies were
purchased from Jackson ImmunoResearch laboratories.
Horseradish peroxidase-labeled anti-mouse IgG (1:1000
dilution), anti-rat (1:500) were used as secondary anti-
bodies followed by chemiluminescence detection (Santa
Cruz Biotechnology).Localization of PfI2
For an episomal expression of PfI2-GFP, the full-length
coding region of PfI2 was amplified by PCR using the
primers Pr23 and Pr24 (Additional file 1: Table S1)
containing XhoI and KpnI restriction sites respectively.
The PCR fragment was cloned into pCR2.1-TOPO vec-
tor (Invitrogen) and its nucleotide sequence was veri-
fied. The PCR product was then subcloned in frame
with GFP into pARL vector (Kind gift of the Dr C.
Sanchez Heidelberg, Germany) [47] digested with XhoI
and KpnI. The plasmid carries the human dhfr gene for
selection with WR99210 and the PfCRT promoter.
The populations of stably transfected parasites were
obtained after 6 weeks. Live parasites were analysed and
images were recorded by fluorescence microscopy
(Zeiss, LSM710).Generation of P. falciparum transgenic parasites
The PfI2 disruption plasmid (pCAM-PfI2) was generated
by inserting a PCR product corresponding to a 5′ portion
from the PfI2 sequence (720 bp) into the pCAM-BSD
vector which contains a cassette conferring resistance to
blasticidin. The insert was obtained using 3D7 genomic
DNA as template and the oligonucleotides Pr19 and Pr20
(Additional file 1: Table S1), which contain PstI and
BamHI sites respectively. Attempts to check the accessi-
bility of PfI2 locus were performed by transfecting wild
3D7 parasites with 3′ tagging constructs. To this end, the
3′ end of the PfI2 sequence (695 bp, omitting the stop
codon) was amplified by PCR using 3D7 genomic DNA
and the primers Pr21 and Pr22 containing PstI and
BamHI restriction sites respectively. The 3′ tagging plas-
mids were generated by inserting the PCR product into
PstI and BamHI sites of the pCAM-BSD-hemagglutinin
(HA). Transfections were carried out by electroporation
of ring stage 3D7 parasites with 75–100 μg of plasmid
DNA, according to Sidhu et al. [78]. To select trans-
formed parasites, 48 h after transfection, Blasticidin
(Invivogen) was added to a final concentration 2.5 μg/ml.
Resistant parasites appeared after 3–4 weeks and were
maintained under drug selection.Genotype and phenotype analysis of P. falciparum
transfectants
To check the presence of correct constructs in transfected
parasites, plasmid rescue experiments were carried out.
Genomic DNA extracted (KAPA Express Extract, kapa-
BioSystems) from wild or transfected parasites were
used to transform E. coli DH5α cells (Invitrogen). Plasmid
DNA was then purified from bacterial clones and digested
with PstI and BamHI.
Genotypes of PfI2 knock-out parasites were analyzed by
PCR on genomic DNA using standard procedures with
the primers Pr 27 (derived from the 5′ non-translated re-
gion and not present in the construct) and Pr26 specific
for the pCAM-BSD vector. Genotypes of PfI2 knock-in
were analyzed using the primer Pr19 and Pr 28 (reverse
primer corresponding to HA).
Assays for PfPP1 and effect of PfI2
The activity of PfPP1 with p-nitro-phenylphosphate (pNPP)
was assayed as previously described [28]. To investigate the
role of PfI2 recombinant proteins or PfI2/PfI3 derived pep-
tides on His6-PfPP1 activity, different amounts of proteins
were added to 1 μg of PfPP1 recombinant protein and
preincubated for 30 min at 37°C before testing the PfPP1
phosphatase activity. Okadaic acid was used as control (data
not show). Results are presented as mean of increase or de-
crease of phosphatase activity in comparison to His6-PfPP1
incubated in the reaction buffer.
Yeast two-hybrid assays
The full length PfPP1 was cloned into the pGBKT7 vector
containing the DNA binding domain of gal4 (Gal4-BD)
and wild-type, deleted or mutated PfI2 (PfI2WT, PfI2(1–
94), PfI2(19–144), PfI2W16A, PfI2Y103A) into pGADT7
containing the gal4 activation domain (Gal4-AD). The
pGBKT7-Gal4-BD-PfPP1 construct was used to transform
Y187 strain and maintained on SD media without tryp-
tophan (SD-W). The pGADT7-Gal4-AD-PfI2 constructs
were used to transform AH 109 strain and maintained
on SD media lacking leucine (SD-L). Mating these two
haploid strains results in the formation of diploid strain,
which is viable on SD media lacking leucine and trypto-
phan (SD-LW). Interaction of PfPP1 with the different
versions of PfI2 proteins were evaluated by their capacity
to grow on selective media: SD medium lacking leucine,
tryptophan and histidine (SD-LWH) and SD medium
lacking leucine, tryptophan, histidine and adenine (SD-
LWHA) for 4 days. Yeasts transformed with empty vector
or with pGBKT7 laminine were used as controls.
Induction of Xenopus oocytes germinal vesicle breakdown
and co-immunoprecipitation
Preparation of Xenopus oocytes and microinjection ex-
periments were performed as previously described [79].
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two or three different animals were microinjected with
His6-PfI2 (wild type, deleted or mutated) recombinant
proteins or PfI2/PfI3 derived peptides. Preliminary ex-
periments using different concentrations ranging from
40 to 120 ng per injection showed that 100 ng of PfI2
was sufficient to induce the highest rate of GVBD.
Okadaic acid was used as a positive control for ability of
oocytes to respond to PP inhibition (data not shown).
Regarding the pre-injection experiments, deleted, mu-
tated His6-PfI2 proteins or PfI2/PfI3 derived peptides
were pre-injected (100 ng) in the oocytes 1 hour before
the His6-PfI2WT injection (100 ng). GVBD was detected
by the appearance of a white spot at the apex of the ani-
mal pole after 15 hours. Oocyte extracts were prepared
as follow: oocytes were lysed in buffer (50 mM HEPES
pH 7.4, 500 mM NaCl, 0.05% SDS, 0.5% Triton X100, 5
mM MgCl2, 1 mg/ml bovine serum albumin, 10 μg/ ml
leupeptin, 10 μg/ml aprotinin, 10 μg/ml soybean trypsin
inhibitor, 10 μg/ml benzamidine, 1 mM PMSF, 1 mM
sodium vanadate) and centrifuged at 4°C for 15 min at
10,000 g. To detect His6-PfI2 proteins in injected ex-
tracts, electrophoresis followed by western-blot analysis
performed on oocytes extracts. The membranes were de-
veloped with anti-His mAb antibody (Qiagen).
To examine the interaction of PfI2WT with XePP1,
we carried out co-immunoprecipitation experiments
with extracts from oocyte injected with PfI2 using
anti-His mAb antibodies (1:100) (Qiagen) or anti-rabbit
antibodies (1/100) (Santa Cruz Biotechnology) in the
presence of sepharose-protein G. Elutes were analysed
as described above using anti-PP1 antibodies (Santa-
Cruz Biotechnology) (1:15 000) or by anti-His
antibodies (1:10 000) and the advanced ECL detection
system (Santa Cruz Biotechnology).
Binding of PfPP1 with synthetic peptides derived from PfI2
The peptides listed in the supplementary Additional file 3:
Table S2 were purchased from Genscript (USA) with a
purity > 98%. All peptides were solubilized in PBS and
used in an ELISA based assay as previously described [80].
Plates were coated with 50 μg/ml (100 μl) of each peptide
proteins or 10 μg/ml of PfI2WT in PBS overnight at 4°C.
Following washing with PBS-Tween20 0.1%, the plates
were blocked with PBS containing 0.5% gelatine for 1 hour
at room temperature. Coated-plates were then incu-
bated with different concentrations of biotinylated PfPP1
which has been labelled with biotin-NHS according to the
manufacturer’s instructions (Calbiochem). Incubation of
biotin-PfPP1 with the different peptides or proteins was
performed in PBS-Tween 0.1% at 37°C for 2 hrs. After 5
washes with PBS-Tween 0.1%, binding was detected using
streptavidin-HRP. After a period incubation of 30 min and
5 washes, TMB substrate (Uptima) was added and thereaction stopped using 2 N HCl. The OD was measured
on an ELISA plate reader (Dynex MRX II) at 450 nm.
Growth inhibition assay of P. falciparum
Assays were carried out in 96-well plates with a starting
parasitemia of 0.5% at a haematocrit of 1% using SYBR
Green I [81]. The peptides were added to the culture at
different concentrations ranging from 80 μM to 1.25 μM
(final concentrations) in a volume of 250 μl of RPMI-
AlbuMAX (0.5%) and incubated for further 72 hr to
allow all stages to complete at least one cycle. Cultures
were stained for 30 minutes in the dark with SYBR
Green I 1X (Invitrogen) diluted in 20 mM Tris pH8.8,
138 mM NaCl, and fixed with 1% paraformaldehyde.
Fixed pRBC were stored at 4°C in the dark until flow cy-
tometry analysis.
Parasite growth was assessed by flow cytometry on a
FACSCalibur (Becton-Dickinson). Infected and uninfected
erythrocytes were gated on the basis of their forward scat-
ter (FSC) and side scatter (SSC) signals. Fluorescence ana-
lysis (Green fluorescence, FL-1 filter) was performed with
CellQuest software (FACScan; BD Biosciences) on a total
of 100,000 acquired events. Fluorescence was observed as
described by Izumiyama et al. [82] on a two-parameters
dot plot (FL1-SSC). Fluorescence of non-infected RBC
was adjusted to plot between 100 and 101. Results are
expressed in percentage of fluorescence among total RBC.
The drug concentration resulting in 50% inhibition of
parasite growth (IC50) was assessed by determining the drug
concentration corresponding to 50% of the parasitaemia ob-
served in the peptide-free control wells. The IC50 value was
calculated using the ICEstimator software [83] based on a
non-linear regression analysis of log-based dose–response
curves. Results are presented asmeans ± sem.
Analysis of peptide uptake by P. falciparum infected red
blood cells
FITC-labeled P1 and P5 peptides were added at a final
concentration of 20 μM to 3D7 P. falciparum infected
erythrocytes (10% parasitaemia). The parasite nucleus
was stained using DAPI (Sigma-Aldrich). FITC-labeled
P1 and P5 peptide penetration was analysed by fluores-
cence microscopy (Zeiss, LSM710).
Toxicity studies
The cytotoxic effect of peptides was assessed using murine
splenocytes stimulated by concanavalin A [81]. Cells iso-
lated from BALB/c mice and washed twice in RPMI 1640
medium, were resuspended in RPMI 1640 supplemented
with 1X non-essential amino acids (Invitrogen), 4 mM
glutamine (Cambrex), 10% FBS, 5 μg/ml gentamycin,
50 μM β-mercaptoethanol (Merck), and 1 μg/ml conca-
navalin A (Sigma). Cells (2.105 cells /well in 100 μl) were
then seeded into 96-well flat-bottom tissue culture plates
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culture medium. The plates were incubated for 72 h in a
humidified atmosphere at 37°C and 5% CO2. 20 μl of a
stock solution of resazurin (alamar Blue, AbD Serotec,
Oxford UK) were then added per well (final concentration
10 μM), and the plates were further incubated at 37°C for
24 h. Optical densities were measured in a DYNEX MRX
II plate reader with excitation wavelength at 570 nm and
emission wavelength at 620 nm. The calculations (differ-
ence in reduction between control and treated cells) were
done according to the recommendations of manufacturer
(AbD Serotec). The 50% inhibiting concentration of cell
proliferation (IC50) were calculated by locating the x-axis
values corresponding to one-half of the absorbance values.
Results are presented as means ± sem.
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Additional file 1: Table S1. List of the primers used throughout this
study.
Additional file 2: Figure S1. Nucleotide sequence of P. falciparum
inhibitor 2. Sequence of PfI2 obtained by RT-PCR using different sets of
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